GoAI
Get started
Absci Corporation logo

Absci Corporation

ABSI

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$9.55

+$0.27 · +2.91%

Aug 21, 4:00 PM ET

Pre-market

$9.53

−$0.02 · -0.21%

Aug 24, 6:31 AM ET

ABSI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

7

Overpriced

Momentum

71

Gaining

Sentiment

64

Bullish

Risk resilience

44

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Sean McClain
Listed since
Jul 22, 2021
Employees
140

Market position

Day range

Current $9.55

52-week range

Current $9.55

Open
$9.56
Previous close
$9.28
Volume
2.33M
0.46× average
Average volume
5.08M
Average daily volume
Market cap
1.62B USD
Beta
2.43
Market reference 1
50-day average
$9.0092
+6.00% above average
200-day average
$4.99
+91.38% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
462.63M USD
P/E (TTM)
-11.94×
P/B (TTM)
6.11×
P/S (TTM)
1,036.37×
EV / EBITDA
-4.48×
Earnings yield
-24.13%
Free cash flow yield
-19.70%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-255.93%
Operating margin
-8411.27%
Net margin
-7756.37%
Return on equity
-60.80%
Return on assets
-53.25%
Return on invested capital
-63.56%

Financial health

Debt / equity
0.01×
Current ratio
6.57×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends94%-1560%-3214%-4868%Gross margin, FY2021: -832.37%Gross margin, FY2022: -925.02%Gross margin, FY2023: -731.88%Gross margin, FY2024: -1277.57%Gross margin, FY2025: -319.36%Operating margin, FY2021: -1573.36%Operating margin, FY2022: -1857.49%Operating margin, FY2023: -2020.20%Operating margin, FY2024: -2401.59%Operating margin, FY2025: -4454.21%Net margin, FY2021: -2111.25%Net margin, FY2022: -1825.37%Net margin, FY2023: -1933.65%Net margin, FY2024: -2274.06%Net margin, FY2025: -4113.68%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -832.37%. Gross margin FY2022 -925.02%. Gross margin FY2023 -731.88%. Gross margin FY2024 -1277.57%. Gross margin FY2025 -319.36%. Operating margin FY2021 -1573.36%. Operating margin FY2022 -1857.49%. Operating margin FY2023 -2020.20%. Operating margin FY2024 -2401.59%. Operating margin FY2025 -4454.21%. Net margin FY2021 -2111.25%. Net margin FY2022 -1825.37%. Net margin FY2023 -1933.65%. Net margin FY2024 -2274.06%. Net margin FY2025 -4113.68%.

Income trends

Revenue

2.8M USD-38.24%

Operating income

−124.72M USD-14.54%

Net income

−115.18M USD-11.71%
Income trends across reported periods18.79M USD−33.39M USD−85.58M USD−137.76M USDRevenue, FY2021: 4.78M USDRevenue, FY2022: 5.75M USDRevenue, FY2023: 5.72M USDRevenue, FY2024: 4.53M USDRevenue, FY2025: 2.8M USDOperating income, FY2021: −75.24M USDOperating income, FY2022: −106.75M USDOperating income, FY2023: −115.52M USDOperating income, FY2024: −108.89M USDOperating income, FY2025: −124.72M USDNet income, FY2021: −100.96M USDNet income, FY2022: −104.9M USDNet income, FY2023: −110.57M USDNet income, FY2024: −103.11M USDNet income, FY2025: −115.18M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.78M USD. Revenue FY2022 5.75M USD. Revenue FY2023 5.72M USD. Revenue FY2024 4.53M USD. Revenue FY2025 2.8M USD. Operating income FY2021 −75.24M USD. Operating income FY2022 −106.75M USD. Operating income FY2023 −115.52M USD. Operating income FY2024 −108.89M USD. Operating income FY2025 −124.72M USD. Net income FY2021 −100.96M USD. Net income FY2022 −104.9M USD. Net income FY2023 −110.57M USD. Net income FY2024 −103.11M USD. Net income FY2025 −115.18M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.8M USD4.53M USD5.72M USD5.75M USD4.78M USD
Cost of goods sold11.74M USD62.46M USD47.57M USD58.91M USD44.59M USD
Gross profit−8.94M USD−57.93M USD−41.85M USD−53.16M USD−39.8M USD
Research and development81.42M USD63.86M USD48.07M USD58.91M USD44.59M USD
Selling, general, and administrative35.06M USD————
Operating expenses115.78M USD50.96M USD73.67M USD53.59M USD35.43M USD
Interest expense209K USD565K USD1.01M USD972K USD3.43M USD
Depreciation and amortization11.74M USD13.39M USD14M USD13.04M USD6.65M USD
Operating income−124.72M USD−108.89M USD−115.52M USD−106.75M USD−75.24M USD
Net income−115.18M USD−103.11M USD−110.57M USD−104.9M USD−100.96M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-12.37%
11 comparable reports
Latest EPS result
-0.18
Estimate -0.19 · Beat by 5.77%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.13-0.18-0.24-0.29Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 18, 2025: actual -0.25, estimate -0.22, surprise -13.64%, Miss. Q2 2025, reported May 13, 2025: actual -0.21, estimate -0.23, surprise +8.70%, Beat. Q3 2025, reported Aug 12, 2025: actual -0.24, estimate -0.19, surprise -26.32%, Miss. Q4 2025, reported Nov 12, 2025: actual -0.2, estimate -0.19, surprise -5.26%, Miss. Q1 2026, reported Mar 24, 2026: actual -0.23, estimate -0.16, surprise -43.75%, Miss. Q2 2026, reported May 7, 2026: actual -0.19, estimate -0.2, surprise +5.00%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.18, estimate -0.191, surprise +5.77%, Beat. Q4 2026, reported Nov 16, 2026: actual —, estimate -0.15, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.57M3.78M1.98M182.75KQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 18, 2025: actual 665K USD, estimate 4.87M USD, surprise -86.34%, Miss. Q2 2025, reported May 13, 2025: actual 1.18M USD, estimate 1.3M USD, surprise -9.31%, Miss. Q3 2025, reported Aug 12, 2025: actual 593K USD, estimate 5.17M USD, surprise -88.54%, Miss. Q4 2025, reported Nov 12, 2025: actual 378K USD, estimate 1.38M USD, surprise -72.63%, Miss. Q1 2026, reported Mar 24, 2026: actual 650K USD, estimate 1.34M USD, surprise -51.45%, Miss. Q2 2026, reported May 7, 2026: actual 215K USD, estimate 1.26M USD, surprise -82.89%, Miss. Q3 2026, reported Aug 11, 2026: actual 300K USD, estimate 919.58K USD, surprise -67.38%, Miss. Q4 2026, reported Nov 16, 2026: actual —, estimate 697.57K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$12.40

29.84% upside
Past 12 months12-month forecastHigh $16.00Average $12.40Low $9.00

Rating distribution

13 ratings
Strong buy00%
Buy1077%
Hold18%
Sell215%
Strong sell00%

Recent analyst actions

7 institutions

ABSI news

247wallst.com

AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next

On August 14, 2026, Advanced Micro Devices (NASDAQ:AMD | AMD Price Prediction) filed its first-ever 13F, pulling back the curtain on a $1.31 billion equity portfolio concentrated in just six positions.

Read source
zacks.com

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

Read source
seekingalpha.com

Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript

Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Absci Q2 Earnings Call Highlights

Absci NASDAQ: ABSI outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis, while reporting a larger…

Read source
globenewswire.com

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and…

Read source
247wallst.com

The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)

Anthropic is preparing what could be the largest IPO of 2026, and it's telling investors the pitch goes well beyond chatbots. According to the Wall Street Journal, "Anthropic is targeting a public debut in September or…

Read source

ABSI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ABSI

Funds reporting this stock among their holdings, ordered by reported position size.

ARK Genomic Revolution ETF logoARK Genomic Revolution ETFARKG
Market value
102.27M
Weight
4.93%
AUM
1.56B USD
Expense ratio
0.75%
Price / 1D
$49.45+3.80%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
50.37M
Weight
0.44%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
34.72M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
32.75M
Weight
0.04%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
12.28M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
9.9M
Weight
0.07%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
9.31M
Weight
0.09%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
6.24M
Weight
0.03%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research ABSI

research.disclaimer